20+ Year Medical Affairs and Ophthalmology Veteran, Lanita C. Scott, M.D., Appointed as Vice President of Clinical Research and Medical Affairs
Karen M. Carroll, RN, Named Vice President of Clinical Development Operations
GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 14, 2018 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the appointments of Lanita C. Scott, M.D., to the position of Vice President of Clinical Research and Medical Affairs and Karen M. Carroll, RN, to the position of Vice President of Clinical Development Operations.
“We are delighted to announce the continued enhancement of our clinical and medical leadership teams with the appointments of these two highly accomplished individuals, Dr. Scott and Ms. Carroll,” said Sue Washer, President and CEO of AGTC. “Having the added expertise to efficiently execute quality clinical trials and more effectively engage with physicians reinforces our strong foundation and will further our success in developing gene therapies aimed at treating rare, inherited retinal diseases.”
Dr. Scott brings more than 20 years of experience in medical affairs to her new role, with a proven track record in strategic research, product positioning, publication planning, key opinion leader development and clinical trial design. She also led her own ophthalmology/glaucoma private practice for several years. Prior to joining AGTC, Dr. Scott served as Head, Global Strategic Research, Senior Medical Director, and Global Medical Affairs for Santen, Inc., where she successfully implemented a Global Strategic Research function, including organizational design, governance and infrastructure needs assessment and resource recommendations. In addition, Dr. Scott also served as Assistant Medical Director, Ophthalmology, for leading biotech manufacturer Genentech, Inc., Associate Medical Director, Medical Affairs, for Regeneron Pharmaceuticals, Inc., and Senior Medical Director, Global Medical Affairs for Allergan, Inc.
Ms. Carroll is a registered nurse and experienced clinical operations professional, with extensive experience in rare disease drug development. Most recently, she served as Vice President of Clinical Operations at Promedior, where she contributed to the successful business development deal with Bristol Myers Squibb, completed enrollment of a global Phase 2 clinical trial ahead of schedule and lead the global team to successful data read out. Prior to this, Ms. Carroll served on the clinical operations team at Vertex, where she was selected to reinvigorate the Incivek Phase 3 trial from delayed site activation and enrollment, leading the team to complete the study on time despite initial delays. While at Vertex, she also led the Kalydeco Phase 3 startup team to record-breaking site start up and activations. Ms. Carroll is a welcome addition to the AGTC executive team as she brings a passion for fulfilling the unmet needs of patients and an ability to lead successful clinical development teams.
AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), and achromatopsia (ACHM CNGB3 & ACHM CNGA3). In addition to its clinical trials, AGTC has preclinical programs in optogenetics, adrenoleukodystrophy (ALD), which is a disease of the central nervous system (CNS), and otology. The clinical-stage XLRS and XLRP programs, the discovery program in ALD and two additional ophthalmology programs are being developed in collaboration with Biogen. In addition to its product pipeline, AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.
Forward Looking Statements
This release contains forward-looking statements that reflect AGTC’s plans, estimates, assumptions and beliefs. Forward-looking statements include information concerning possible or assumed future results of operations, business strategies and operations, preclinical and clinical product development and regulatory progress, potential growth opportunities, potential market opportunities and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors. Risks and uncertainties that may cause actual results to differ materially include, among others: gene therapy is still novel with only a few approved treatments so far; AGTC cannot predict when or if it will obtain regulatory approval to commercialize a product candidate or receive reasonable reimbursement; uncertainty inherent in clinical trials and the regulatory review process; risks and uncertainties associated with drug development and commercialization; factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended September 13, 2017, as filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management’s plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754